Pharmacoepidemiology Of Multiple Myeloma Treatment Patterns, Safety And Effectiveness In Real Life Conditions Aurore Palmaro Thesis directors: Dr Maryse.

Slides:

Advertisements

Similar presentations

Palumbo A et al. Proc ASH 2013;Abstract 536.

Advertisements

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.

Treatment For Newly Diagnosed Myeloma

Facon T et al. Proc ASH 2013;Abstract 2.

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.

Richardson PG et al. Proc ASH 2013;Abstract 535.

Palumbo A et al. Proc ASH 2012;Abstract 446.

Carfilzomib: High Single-Agent Response Rate with Minimal Neuropathy Even in High-Risk Patients 1 Baseline Peripheral Neuropathy Does Not Impact the Efficacy.

LaCasce A et al. Proc ASH 2014;Abstract 293.

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma 1,2 The Cardiovascular Impact of Carfilzomib in Multiple Myeloma 3 1 Stewart.

1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates.

Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma: Results from a Phase I Study After Full Enrollment.

Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.

Palumbo A et al. Proc ASH 2014;Abstract 175.

Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients Palumbo A.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

Maintenance Therapy in Myeloma Myeloma Canada National Conference Donna E. Reece, M.D. Princess Margaret Hospital 24 September 2011.

Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.

Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.

Long Term Follow-up on the Treatment of High Risk Smoldering Myeloma with Lenalidomide plus Low Dose Dex (Rd) (Phase III Spanish Trial): Persistent Benefit.

Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.

ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Mark TM et al. Proc ASH 2012;Abstract 77.

A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.

A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.

Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.

Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed or Refractory.

Michel Attal, M.D., Valerie Lauwers-Cances, M.D., Gerald Marit, M.D., Denis Caillot, M.D., Philippe Moreau, M.D., Thierry Facon, M.D., Anne Marie Stoppa,

MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,

Slideset on: Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone.

A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.

Lenalidomide plus dexamethasone is more effective than dexamethasone alone inpatients with relapsed or refractory multiple myeloma regardless of prior.

New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida ARRAY : Phase II Trial of Carfilzomib.

Use of generic antiretroviral in Patients with HIV : Pharmaco-epidemiological impact Thesis project conducted by Mr. Joseph RWAGITINYWA, PhD candidate.

Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.

The Stages of a Clinical Trial

Myeloma hope new treatment in the horizon

Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)1 CC-486 (Oral.

1 Stone RM et al. Proc ASH 2015;Abstract 6.

Palumbo A et al. Proc ASH 2012;Abstract 200.

Attal M et al. Proc ASH 2010;Abstract 310.

Korde N et al. Proc ASH 2012;Abstract 732.

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.

Pomalidomide Plus Low-Dose Dex vs High-Dose Dex in Rel/Ref Myeloma

Potentially inappropriate drug prescribing in Nursing Homes

IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.

Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.

Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al

Mateos MV et al. Proc ASH 2013;Abstract 403.

Presented By Luca Malorni at 2017 ASCO Annual Meeting

Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.

San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Intervista a Angelo Delmonte

Background and update from Myeloma XI Dr John Jones

The Nurse View: Best Practices in Multiple Myeloma

Niesvizky R et al. Proc ASH 2010;Abstract 619.

Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.

Palumbo A et al. Proc ASCO 2011;Abstract 8007.

Vesole DH et al. Proc ASH 2010;Abstract 308.

Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)1 Final Results from.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.

Boccadoro M et al. Proc ASCO 2011;Abstract 8020.

Maintenance therapies in Multiple Myeloma

Presentation transcript:

Pharmacoepidemiology Of Multiple Myeloma Treatment Patterns, Safety And Effectiveness In Real Life Conditions Aurore Palmaro Thesis directors: Dr Maryse Lapeyre Mestre and Dr Fabien Despas Doctoral School Biologie Santé Biotechnologies. Start date: Nov 2013 UMR INSERM 1027, Equipe 6 Pharmaco-épidémiologie, évaluation de l'utilisation et du risque médicamenteux INTRODUCTION AXIS 1: EXPLORING PATTERNS OF USE CONCLUSION AND PERSPECTIVES REFERENCES AND SUPPORT Study design: population- based cohort study Population: newly diagnosed MM patients selected among Midi-Pyrénnées SNIIRAM Beneficiaries Exposure of interest: alkylants, imids, proteasome inhibitors Endpoints: combination used, duration and number of cycle, adherence to recommendations in terms of dose, periodicity and number of cycles and previous therapy Palmaro A, Despas F, Protin C, Hebraud B, Montatsruc JL, Laurent G, Lapeyre-Mestre M. Determinants of non-adherence with lenalidomide and thalidomide in multiple myeloma: a cohort study in outpatient settings.IXème Congrès de Physiologie, de Pharmacologie et de Thérapeutique, P2T, Poitiers, avril 2014 (communication affichée) AXIS 2: CONCOMITANT DRUGS AND SAFETY Study design: nationwide population-based cohort study Population: newly diagnosed MM patients selected among SNIIRAM Beneficiaries Exposure of interest: Imids: thalidomide, lenalidomide and pomalidomide Endpoints: occurrence of selected events (thrombosis, liver injuries,..) AXIS 3: SURVIVAL IN REAL LIFE SETTINGS Study design: nationwide population-based cohort study Population: newly diagnosed MM patients selected among SNIIRAM Beneficiaries Exposure of interest: autologous or allogeneic stem cell transplantation, conventional chemotherapy, imids, proteasome inhibitors Endpoints: Overall Survival and Progression Free Survival at 12, 24 and 36 months Management and therapeutic outcomes of certain cancer have been considerably improved by new therapies. Some of these new therapies are proposed as oral formulations, and offer the opportunity to pursuit treatment in ambulatory care settings. These drugs are based on different treatment sequences and a longer duration of therapy compared to traditional chemotherapy. Theses aspects, combined with a prolongation of survival time, contribute to the idea that cancer could, in some way, be assimilated to a chronic disease. However, beyond their benefits, some of these new drugs are raising new issues, in relation with their long term administration, their potential for delayed effect or interactions with other drugs. Their administration outside hospital settings require considering patient adherence and compliance, exposure to other drugs, and management of adverse reactions. Even if acute effects are mainly described during phase III clinical trials, new toxicity data can arise as a result of exposure of patients with different comorbidities or exposed to a wide range of different drugs. Resulting events or interactions can affect the therapeutic outcomes of treated patients, including their survival. As a consequence, therapeutic outcomes (response to treatment, overall survival, etc.) and toxicity for targeted therapies need to be investigated in real life settings. These investigations will be implemented for multiple myeloma. The prognosis of patients suffering from this B-cell malignancy has been considerably improved by 3 agents, thalidomide, lenalidomide, and bortezomib. The overall objective will be to describe the patterns of use of drugs for multiple myeloma and their safety and effectiveness in a real life perspective This work is supported by the programme "Investissements d'avenir" ANR-11-PHUC-001 The research is expected to provide new evidence and to update data from clinical trials on safety profile and outcomes of therapies used in multiple myeloma. The findings could lead to identify patient profiles, risk factors or risk period that could support recommendations to adapt follow-up of patients treated with these therapies in ambulatory settings.